Free Trial
NASDAQ:AARD

Aardvark Therapeutics (AARD) Stock Price, News & Analysis

Aardvark Therapeutics logo
$10.58 +0.37 (+3.62%)
As of 10:50 AM Eastern

About Aardvark Therapeutics Stock (NASDAQ:AARD)

Key Stats

Today's Range
$10.23
$10.70
50-Day Range
$7.00
$12.86
52-Week Range
$4.88
$19.58
Volume
2,259 shs
Average Volume
108,128 shs
Market Capitalization
$229.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.25
Consensus Rating
Buy

Company Overview

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Receive AARD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aardvark Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AARD Stock News Headlines

Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
Cantor Fitzgerald Analysts Raise Earnings Estimates for AARD
See More Headlines

AARD Stock Analysis - Frequently Asked Questions

Aardvark Therapeutics' stock was trading at $13.30 at the beginning of 2025. Since then, AARD shares have decreased by 23.2% and is now trading at $10.21.
View the best growth stocks for 2025 here
.

Aardvark Therapeutics, Inc. (NASDAQ:AARD) issued its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.01.

Aardvark Therapeutics (AARD) raised $100 million in an initial public offering (IPO) on Friday, February 14th 2025. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets acted as the underwriters for the IPO.

Aardvark Therapeutics' top institutional investors include Decheng Capital LLC (18.06%), Cormorant Asset Management LP (3.69%), Braidwell LP (2.30%) and Adage Capital Partners GP L.L.C. (1.15%). Insiders that own company stock include Tien-Li Lee and Nelson Sun.
View institutional ownership trends
.

Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/14/2025
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AARD
Previous Symbol
NASDAQ:AARD
Web
N/A
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.25
High Stock Price Target
$50.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+206.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$221.52 million
Optionable
N/A
Beta
N/A
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:AARD) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners